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Abstract
Background: Activation of bone morphogenetic protein (BMP)4 signalling in human ovarian cancer cells induces a
number of phenotypic changes in vitro, including altered cell morphology, adhesion, motility and invasion, relative
to normal human ovarian surface epithelial cells. From these in vitro analyses, we had hypothesized that active
BMP signalling promotes the metastatic potential of ovarian cancer.
Methods: To test this directly, we engineered OVCA429 human ovarian cancer cells possessing doxycycline-
inducible expression of a constitutively-active mutant BMP receptor, ALK3
QD, and administered these cells to
immunocompromised mice. Further characterization was performed in vitro to address the role of activated BMP
signalling on the EOC phenotype, with particular emphasis on epithelial-mesenchymal transition (EMT) and cell
adhesion.
Results: Unexpectedly, doxycycline-induced ALK3
QD expression in OVCA429 cells reduced tumour implantation on
peritoneal surfaces and ascites formation when xenografted into immunocompromised mice by intraperitoneal
injection. To determine the potential mechanisms controlling this in vivo observation, we followed with several cell
culture experiments. Doxycycline-induced ALK3
QD expression enhanced the refractile, spindle-shaped morphology of
cultured OVCA429 cells eliciting an EMT-like response. Using in vitro wound healing assays, we observed that ALK3
QD-
expressing cells migrated with long, cytoplasmic projections extending into the wound space. The phenotypic
alterations of ALK3
QD-expressing cells correlated with changes in specific gene expression patterns of EMT, including
increased Snail and Slug and reduced E-cadherin mRNA expression. In addition, ALK3
QD signalling reduced b1- and
b3-integrin expression, critical molecules involved in ovarian cancer cell adhesion. The combination of reduced
E-cadherin and b-integrin expression correlates directly with the reduced EOC cell cohesion in spheroids and reduced
cell adhesion to the extracellular matrix substrates fibronectin and vitronectin that was observed.
Conclusions: We propose that the key steps of ovarian cancer metastasis, specifically cell cohesion of multicellular
aggregates in ascites and cell adhesion for reattachment to secondary sites, may be inhibited by overactive BMP
signalling, thereby decreasing the ultimate malignant potential of ovarian cancer in this model system.
Background
Ovarian cancer is the most lethal of the gynaecologic
malignancies in the Western world. The majority of
ovarian cancers are detected as late-stage disease and
involve the dissemination of tumour cells throughout
the peritoneal cavity and the production of ascites; these
clinical assessments are correlated with a very poor
prognosis (only 5-40% five-year survival) for patients[1].
Successful early detection and more effective manage-
ment of late-stage disease are crucial to improving the
survival and quality-of-life of ovarian cancer patients.
Understanding the underlying molecular mechanisms of
ovarian cancer pathogenesis is key to achieving this goal.
Previous work from our laboratory demonstrated that
normal human ovarian surface epithelial (OSE) cells and
human epithelial ovarian cancer (EOC) cells possess an
intact autocrine bone morphogenetic protein-4 (BMP4)
signalling pathway[2]. BMPs comprise approximately 20
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(TGFb) superfamily of cytokines[3]. BMPs act as extra-
cellular dimeric ligands by binding to the type I (ALK2,
ALK3, and ALK6) and type II (BMPR2) receptors[4].
BMP signalling is mediated via a heterotetrameric recep-
tor complex composed of a type I receptor that is phos-
phorylated at the intracellular GS domain by type II
receptor serine/threonine kinase activity, leading to the
association of receptor-activated Smad (R-Smad) pro-
teins. Upon phosphorylation, the BMP-specific R-Smads
(Smads 1, 5 and 8) dimerize and associate with the com-
mon-mediator Smad, Smad4. This activated Smad com-
plex translocates to the nucleus and regulates the
transcription of target genes, typically via its interaction
with several other transcription factors and co-activator
and co-repressor proteins[5]. Recent work also shows
that Smad independent signalling can be initiated by the
activated receptor complex[4,6,7].
The multifaceted and complicated roles of TGFb sig-
nalling in the pathogenesis of many human cancers is
well established[8,9], yet our understanding of the con-
tribution of BMP signalling to cancer biology is limited.
In many instances, activation of BMP signalling inhibits
cell growth and induces apoptosis in different cancer
cell types[10-16]. The identification of inactivating
germline mutations in the human BMPR1A gene
(encoding the ALK3 receptor) in juvenile polyposis
patients indicates a putative tumour suppressor function
of active BMP signalling in colon cancer[17,18]. How-
ever, other studies have found that BMP signalling may
be implicated in increasing metastatic potential[19-21]
and tumour angiogenesis[22]. While there has been
some advancement in our understanding of the func-
tional implications of BMP signalling in various cancers,
the contribution of BMP signalling to ovarian cancer
pathogenesis requires further clarification.
Treatment of primary human OSE and EOC cells with
exogenous BMP4 ligand results in a cell spreading phe-
notype and increased cell adhesion[2,23]. Furthermore,
BMP4 induces an epithelial-mesenchymal transition
(EMT) morphologic response in primary EOC cells iso-
lated from patient ascites by increasing Snail and Slug
expression and a subsequent decrease in E-cadherin
[23]. BMP4 directly upregulates ID1 and ID3 proto-
oncogene expression in EOC cells compared with nor-
mal OSE[2], and BMP4 signalling increases EOC cell
motility whereas normal OSE cell motility is unaffected
[23]. We sought to develop a model system to elucidate
the function of active BMP signalling in ovarian cancer
metastasis. We chose to use the human ovarian cancer
cell line OVCA429 which is capable of producing ascites
and peritoneal implants mimicking the spread of ovarian
cancer observed in patients [24]. To this end, we
employed a doxycycline (Dox)-inducible expression
system in OVCA429 cells to ectopically express a con-
stitutively-active mutant BMP type I receptor (ALK3
QD).
Herein, we report that constitutively-active ALK3 recep-
tor signalling decreases the intraperitoneal dissemination
of OVCA429 cells in nude mouse xenografts. We pro-
vide further evidence that this may occur via downregu-
lation of E-cadherin and b1-/b3-integrin expression
thereby reducing cell-cell cohesion and cell-substratum
adhesion. The application of this model system to an in
vivo context provides insight into how cellular responses
affected by constitutive BMP signalling directly impacts
ovarian cancer metastasis.
Methods
Cell culture
CaOV3 and SkOV3 human ovarian cancer cells were
g r o w ni nD u l b e c c o ’s modified Eagle medium (Invitro-
gen) containing 10% heat-inactivated fetal bovine serum
(FBS; Hyclone). OVCA429 human ovarian cancer cells
(gift of Dr. B. Vanderhyden, Ottawa Regional Cancer
Centre) were grown in Minimal essential medium Eagle-
alpha (Invitrogen) containing 10% FBS and supplemen-
ted with 0.1 mM non-essential amino acids (Invitrogen).
Primary cultures of human OSE and EOC cells were
isolated and maintained as previously described[25].
Treatment of OVCA429 cells with recombinant human
BMP4 (R&D Systems) was performed as described pre-
viously[2]. Institutional approval for research with
human materials was received prior to the initiation of
these studies (QEII Health Sciences Centre, Research
Ethics Committee, #QE-RS-99-016; IWK/Grace Hospital
Research Ethics).
OVCA429 Tet-On cells (429T cells) were generated
by transfecting OVCA429 cells with pTet-On vector
(Clontech) using GeneJuice reagent (Novagen), followed
by selection with 1 mg/mL Geneticin™ (Invitrogen). Of
the 27 separate clones generated, 5 clones displayed
detectable doxycycline-inducible activity, as assessed by
transient transfection of the pTRE2-luc vector and fol-
lowed by luciferase assays performed as previously
described[2]. Doxycycline hyclate (Dox; Sigma) was used
at a concentration of 2 μg/mL in all experiments, unless
otherwise indicated. Dox-inducible ALK3
QD-expressing
cells (429T-ALK3
QD) were generated by transfecting
429T cells with pTRE2-ALK3
QD-HA (original pCMV5-
Alk3QDHA plasmid was a gift from Dr. L. Attisano, U.
of Toronto), and selection with 250 μg/mL Hygromycin
B (Invitrogen). Five different 429T-ALK3
QD cell lines
possessing Dox-inducible ALK3
QD expression were
identified by Western blot analysis, and two indepen-
dent clones (clones 429T-A44 and -54) were chosen for
further examination. Subsequent growth of 429T and
429T-ALK3
QD cell lines was maintained using 100 μg/
mL Geneticin™ and 100 μg/mL Hygromycin B.
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Northern analysis was performed as previously described
[2], using radiolabelled pro b e ss y n t h e s i z e df r o mh u m a n
cDNA fragments of ALK3 (nucleotides 145-594), ALK6
(nucleotides 907-1256), BMPR2 (nucleotides 2561-3010),
GAPDH (nucleotides 270-620), ID1 (nucleotides 189-
549), and ID3 (nucleotides 356-750) as templates.
Western analysis
Protein isolation and subsequent Western analyses were
performed as previously described[2]. ALK3
QD protein
expression was detected using anti-HA-Peroxidase 3F10
monoclonal antibody (1:1000 dilution; Roche). The anti-
actin polyclonal antibody (1:1000 dilution; Sigma) followed
by incubation with horseradish peroxidase-conjugated
sheep anti-rabbit IgG secondary antibody (1:5000 dilution;
Chemicon) was used as a control for protein loading.
Tumour cell xenografting
All studies conformed to the approved animal utilization
protocol and Canadian Council for Animal Care guide-
lines. Eight- to 10-week-old female CD-1 nu/nu athymic
nude mice (Charles River) were maintained in a sterile
barrier animal facility. After approximately one week
from receipt, 30 mice were started on a diet of gamma-
irradiated rodent chow containing Dox at a concentration
of 1000 ppm (Research Diets) for 2 d, and another group
of 30 mice remained on the in-house rodent chow diet.
Mice were supplied with food and water ad libitum.E a c h
mouse was injected i.p. with a suspension of 5 × 10
5 cells
(either 429T-ALK3
QD or 429T control) in a volume of
0.2 mL sterile 1 × PBS, resulting in four groups of fifteen
mice (429T-ALK3
QD or 429T controls, with or without
Dox treatment). Mice were monitored for 90 d post-
injection for signs of ascites formation or visible morbid-
ity. At the experimental endpoint (90 d), mice were sacri-
ficed and dissection was performed to assess and quantify
ascites production and tumour formation.
Histology
Tissues harvested for histological analysis were fixed
immediately in 4% paraformaldehyde/1 × PBS, paraffin-
embedded and sectioned at 5 μm then stained with hae-
matoxylin and eosin (tissue processing performed by
Molecular Pathology, Robarts Research Institute, UWO).
Microscopic images of stained tissue sections were cap-
tured using an Olympus IX70 inverted microscope and
Image Pro 6.2 software, and subsequently adjusted for
brightness/contrast and colour balance using Adobe
Photoshop 7.0 software.
RT-PCR
Confirmation of ALK3
QD transgene expression in
tumours that formed in nude mice was performed by
RT-PCR analysis of total RNA isolated from homoge-
nized tissue using the Total RNA isolation kit (Sigma)
as per manufacturer’s instructions. Reverse transcription
was performed with 2 μg of RNA reverse transcribed
into cDNA using oligo-dT decamers as primers and
Superscript II reverse transcriptase (Invitrogen) as per
manufacturer’s instructions. Subsequent PCR was car-
ried out using oligonucleotides that specifically amplify
the 3’ end of the ALK3
QD-HA cDNA construct. Human
GAPDH mRNA expression served as a control for
tumour xenograft material in each sample.
For quantitative RT-PCR analysis, total RNA was iso-
lated from cells treated with 2 μg/mL Dox for 2 days, or
left untreated, and 2 μgo fR N Aw a ss u b s e q u e n t l y
reverse transcribed into cDNA using oligo-dT decamers
as primers and Superscript II reverse transcriptase (Invi-
trogen) as per manufacturer’s instructions. PCR was per-
formed using the Brilliant SYBR green QPCR Master
Mix (Stratagene), and real-time measurement of the
PCR reactions was recorded using the Mx3000P Real-
time PCR System (Stratagene), and quantified using the
2
-ΔΔCt method[26]; GAPDH expression was used for
normalization, and the fold change in mRNA expression
was calculated versus untreated cell samples.
All human gene-specific primer sequences used in
RT-PCR are available upon request.
Scratch wound assays
Cells were seeded at 2 × 10
5 cells in 6-well dishes and
24 h later were treated with 2 μg/mL Dox, or left
untreated. Cells were grown for 2-3 d until confluent
monolayers were achieved, then a wound was created by
scratching the wells with a sterile plastic pipette tip (~1
mm space). After several gentle washes with 1 × PBS,
media was replaced (with or without Dox) and cells
were monitored at multiple timepoints and photo-
graphed at 24 h. Photographic images were captured
using a Nikon Coolpix digital camera and Nikon
inverted phase contrast microscope at 100 ×
magnification.
Adhesion assays
For assessment of cell detachment, cells were seeded at
5×1 0
5 cells in 6-well dishes, and 24 h later were trea-
ted with 2 μg/mL Dox, or left untreated. Detached cells
were quantified as previously described[2].
In adhesion experiments, cell lines were treated with 2
μg/mL Dox, or left untreated, and grown for 2-3 d until
confluent monolayers were achieved. Adhesion assays
were performed as previously described[27]. Cells were
plated at a density of 1 × 10
5 cells/well into 24-well
dishes previously coated with 500 ng/cm
2 fibronectin
or 200 ng/cm
2 vitronectin (Sigma), and blocked
with 1% BSA.
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429T and 429T-ALK3
QD cells were pre-treated with 2
μg/mL Dox for 2 days, or left untreated, while grown in
monolayer culture. One hundred thousand cells/well
were then seeded in quadruplicate into a 24-well Ultra-
Low Attachment cluster plate (Corning) and the same
culture conditions (i.e. +/- Dox) were maintained during
spheroid formation. Images were captured at the 2-day
timepoint using an Olympus IX70 inverted microscope
at 100 × magnification and Image Pro 6.2 software.
Statistical analyses
Statistical analyses were performed using the nonpara-
metric Mann-Whitney test with 95% confidence inter-
vals (GraphPad Prism 4). Values of significance are
indicated in the Legends to Figures.
Results
BMP receptor expression in OSE and EOC cells
Previous work from our laboratory demonstrated that
primary cultures of normal human OSE cells and EOC
cells possess an intact BMP4 signalling pathway, but
more importantly, that primary EOC cells exhibit strik-
ing changes in morphology, adhesion, motility and
invasion in response to BMP4 stimulation[2,23]. Addi-
tionally, EOC cells exhibit heightened responses in gene
expression following treatment with exogenous BMP4 in
comparison to normal OSE cells; for example, ID1 gene
expression is increased ~10- to 15-fold in EOC cells,
compared to 2- to 3-fold in normal OSE[2,23]. To
further our understanding of the potential differential
responses to BMP4 signalling in these cell types, we
quantified BMP receptor expression levels in normal
OSE and EOC cells. BMP4 signalling is mediated pri-
marily by the ALK3, ALK6, and BMPR2 receptors. In
Northern blot analyses using RNA isolated from actively
growing primary cultures of OSE and EOC cells, and
the EOC cell lines CaOV3, SkOV3, and OVCA429, we
readily detected expression of the type I BMP receptor
ALK3 and the type II receptor BMPR2 mRNA (Fig. 1).
After normalization to GAPDH expression, no signifi-
cant differences in the mRNA level of ALK3 or BMPR2
were detectable when normal OSE is compared with
primary EOC samples. Expression of ALK6 mRNA was
largely undetectable in all primary cell samples. Addi-
tionally, we have determined that BMPR2 protein
expression as well as the BMP-specific R-Smads, Smad1
and Smad5, remain unchanged between primary OSE
Figure 1 BMP receptor expression in normal human OSE and human ovarian cancer cells. Northern blot analysis was performed on total
RNA isolated from early-passage primary cultures of normal human OSE cells (OSE3, OSE18, OSE22, and OSE23), primary human EOC cells
(EOC13, EOC14, EOC16, EOC28, and EOC32), and three established human ovarian cancer cell lines (CaOV3, SkOV3, and OVCA429) using probes
specific for ALK3, ALK6, and BMPR2 mRNA. ALK3 and BMPR2 mRNA expression was readily detectable (24 h exposure) in all samples analysed,
whereas ALK6 mRNA expression was observed only in ovarian cancer cell lines after an extended period of time (8 d exposure). Expression of all
three BMP receptors was elevated in the three cell lines versus the primary cultures; however, there was no mean difference in receptor
expression between primary cultures of OSE and EOC cells.
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observations). By comparison, immortalized EOC cell
lines expressed higher levels of ALK3, ALK6,a n d
BMPR2 than the primary cell samples. These data are
consistent with quantitative RT-PCR results (data not
shown) suggesting that ALK3 and BMPR2 are likely the
chief receptors used by BMP4 to confer activated signal-
ling in primary cultures of human OSE and EOC cells.
Constitutive ALK3 receptor signalling reduces metastatic
potential in vivo
Our goal was to examine the consequence of BMP sig-
nalling activity on the metastatic potential of ovarian
cancer cells. We engineered OVCA429 cells that possess
Dox-inducible expression of the mutated BMP type I
receptor ALK3
QD.T h eA L K 3
QD receptor harbours a Q-
to-D point mutation at amino acid 233 in the GS domain
thereby replacing the necessary activation by BMPR2-
mediated phosphorylation in response to BMP ligand
binding [28]. We chose to use OVCA429 cells since they
have a BMP receptor expression profile similar to pri-
mary OSE and EOC cells (Fig. 1), and exhibit robust
BMP4 signalling activity in response to BMP4 treatment
(Fig. 2A). We generated five independent clones of 429T-
ALK3
QD cells, and two of these exhibited low basal
expression in untreated cells with readily-detectable
Figure 2 Generation of human ovarian cancer OVCA429 cells with Dox-inducible expression of the constitutively-active mutant ALK3
receptor (ALK3
QD). (A) Phosphorylation of Smad1 (P-Smad1) and expression of ID1 mRNA are induced in serum-starved OVCA429 cells treated
with 10 ng/mL BMP4 for 30 min and 90 min, respectively. Total Smad1 and actin were used as protein loading controls, and GAPDH for RNA
loading control. (B) Expression of HA-tagged constitutively-active ALK3 receptor (ALK3
QD) was observed by Western analysis in two independent
429T-ALK3
QD stable cell clones (A44 and A54) after 24 h treatment with Dox, as compared with control cells (T7Hyg4). Actin was used as a
control for protein loading. (C) Activated BMP signalling was confirmed by Northern analysis of ID1 and ID3 mRNA expression from 429T-A44
and 429T-A54 cells, and 429T control cells, treated with Dox for 24 h, or left untreated. GAPDH served as a control for RNA loading.
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QD expression in response to treatment with 2 μg/
mL Dox for 24 h (Fig. 2B). As a functional readout to
confirm intact ALK3
QD receptor signalling, we observed
Dox-induction of ID1 and ID3 mRNA expression in
429T-ALK3
QD cells as compared with 429T controls
(Fig. 2C). High basal levels of ID1 expression in untreated
cells is due to the presence of serum in the growth media
required to sustain rtTA expression and Dox-inducible
activity in Tet-On cells.
OVCA429 cells consistently form ascites and intraper-
itoneal tumour lesions when injected directly into the
peritoneal cavity of nude mice [24] thereby providing a
useful in vivo model to study ovarian cancer metastasis.
Female CD-1 nu/nu mice were injected i.p. with 5 × 10
5
cells of 429T-ALK3
QD or 429T controls. Mice were sub-
sequently divided into two groups (n = 15 per group), a
group was either fed a normal chow diet or Dox-con-
taining chow to induce ALK3
QD expression. After an
experimental endpoint of 90-100 d, tumours formed on
several surfaces of the peritoneal cavity and measurable
ascites developed in mice in all four treatment groups
(Table 1). Notably, the proportion of Dox-treated mice
injected with 429T-ALK3
QD cells that developed mea-
surable ascites was reduced when compared to control
mice (28.6% versus 40-46.7%). In addition, we observed
a decrease in the mean number of macroscopic tumour
nodules (≥1 mm) that formed within the peritoneal cav-
ity due to ALK3
QD expression (Fig 3A). Together,
ALK3
QD expression was associated with reduced intra-
peritoneal tumour and ascites formation compared with
controls; however, this difference was not statistically
significant. We noted that the number of animals devel-
oping tumours in the untreated (minus Dox) 429T-
ALK3
QD group had a lower mean number of tumours
(6.2 ± 2.0) than the 429T control groups. This raises the
possibility that ALK3
QD is expressed at very low levels
in the absence of Dox, undetectable by expression analy-
sis, while still producing a modest functional response.
Expression of ALK3
QD was confirmed in tumours that
developed in Dox-treated 429T-ALK3
QD-injected mice
(Fig. 3B). Macroscopic tumours adherent to the perito-
neal wall were observed in tumour-bearing mice, and
histologic analysis demonstrated foci of penetration into
the underlying smooth muscle (Fig. 3C), but this inva-
sion was not evident in tumours isolated from Dox-trea-
ted 429T-ALK3
QD mice. The majority of tumour
nodules were detected in the adipose tissue of the
omentum juxtaposed to the pancreas, and the serosa of
the spleen, intestine and liver (Table 1). Interestingly,
only one Dox-treated 429T-ALK3
QD female mouse har-
boured experimental metastasis to the omentum, the
most common site for tumours in all other groups.
Constitutive ALK3 receptor signalling reduces EOC cell
adhesion in vitro
We next performed a series of experiments to investi-
gate the underlying basis for reduced in vivo metastatic
potential of ovarian cancer cells due to constitutively-
active BMP signalling. A number of genes involved in
cancer metastasis are putative and/or known targets for
active BMP signalling in ovarian cancer cells[23]. A
well-established and distinguishing molecular signature
of epithelia-mesenchymal transition and increased
malignancy is the upregulated expression of Snail and
Slug transcription factors (encoded by SNAI1 and
SNAI2, respectively) and the subsequent downregulation
of their target gene CDH1 encoding E-cadherin[29,30].
By performing quantitative RT-PCR we determined that
Dox-treatment of 429T-ALK3
QD cells led to the 4-fold
upregulation of SNAI1 (Snail) and 2.5-fold upregulation
of SNAI2 (Slug) when compared with 429T control cells
(Fig. 4). In a reciprocal fashion, ALK3
QD signalling
Table 1 Summary of ovarian cancer cell xenograft studies in nude mice.
429T 429T-ALK3
QD
-Dox +Dox -Dox +Dox
n
a 14 15 15 14
No. of mice with ascites (%) 6 (42.9) 7 (46.7) 6 (40.0) 4 (28.6)
Mean ascites volume (± SEM) 1.5 (± 0.9) 1.0 (± 0.6) 0.7 (± 0.4) 1.1 (± 0.5)
No. of mice with tumours (%) 10 (71.4) 9 (60.0) 7 (46.7) 6 (42.9)
Mean tumour number (± SEM) 7.5 (± 2.7) 10.4 (± 3.6) 6.2 (± 2.0) 2.2 (± 1.3)
Tumour sites (number of mice)
b Pw (5) Pw (8) Pw (3) Pw (4)
Spl (4) Int (1) Om (6) Lv (1)
Spl (2) Int (1) Om (8) Lv (4)
Spl (3) Int (2) Om (6) Lv (4)
Spl (2) Int (0) Om (1) Lv (1)
a - Two mice died (not due to tumour growth; cause unknown) prior to the experimental endpoint resulting in 14 mice for the 429T -Dox group and 14 mice for
the 429T-ALK3
QD +Dox group.
b - Number of macroscopic tumour nodules (≥1 mm diameter) was scored. Observed tumour sites (i.e. adherent tumour nodules on tissue/organ surface) were:
peritoneal wall (Pw), spleen (Spl), intestine (Int), omentum (Om) and liver (Lv).
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control cells. As a positive control for activated BMP
signalling, we detected a substantial increase in both
ID1 (~8-fold) and ID3 (~9-fold) mRNA expression in
ALK3
QD-expressing cells (Fig. 4).
Cell adhesion is likely a key checkpoint regulating the
efficient spread of ovarian cancer cells during metastasis.
Potential molecular targets of ALK3
QD signalling med-
iating the observed reduction in ovarian cancer cell
adhesion are genes encoding integrins and/or extracellu-
lar matrix (ECM) components. We performed gene
expression analyses for several specific integrins and
ECM components known to be expressed by OSE and
EOC cells[31,32]. Dox-treated 429T-ALK3
QD cells
possessed a 64% decrease in ITGB1 (b1-integrin) and
43% decrease in ITGB3 (b3-integrin) mRNA expression
versus 429T controls (Fig. 4). In addition, we observed a
reciprocal elevated expression of ECM genes FN1 (fibro-
nectin) and VTN (vitronectin) mRNA in ALK3
QD-
expressing cells by 49% and 69%, respectively.
Similar to previous observations when primary EOCs
and established EOC cell lines were treated with exo-
genous BMP4 ligand [2,23], induction of ALK3
QD did
not affect the overall growth rate of OVCA429 cells
(data not shown). We observed, however, that when
Dox-treated cells reached confluence, both 429T-A44
and 429T-A54 cells had an altered morphology as com-
pared with Dox-treated 429T cells or untreated cells
Figure 3 ALK3
QD reduces intraperitoneal tumour formation. Female CD-1 nu/nu athymic nude mice were injected intraperitoneally with a
suspension of 5 × 10
5 cells (either 429T-ALK3
QD or 429T control cells), resulting in four groups of fifteen mice (each cell line with or without
Dox-containing chow). (A) Fewer Dox-treated mice injected with 429T-ALK3
QD cells developed detectable tumour lesions throughout the
peritoneal cavity when compared with Dox-treated 429T-injected mice. (B) ALK3QD transgene expression in tumours that formed in nude mice
was confirmed by RT-PCR analysis of total RNA with human GAPDH mRNA expression serving as a control for xenograft material present in each
sample. (C) Tumour specimens isolated from 429T-injected and 429T-ALK3
QD-injected mice fed a Dox-containing or normal chow diet were
analyzed histologically by H&E staining. Tumour implants from the peritoneal wall were adherent to the surface of smooth muscle in Dox-
treated 429T-ALK3
QD-injected mice, whereas localized invasion was evident in specimens from the other groups of mice. 100 × original
magnification.
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as a cobblestone epithelial monolayer. Induction of
ALK3
QD expression in 429T-A44 and 429T-A54 cells
produced a more mesenchymal-like cellular phenotype
than uninduced cells, with clusters of refractile, spindle-
shaped cells.
To address whether this altered phenotype in response
to ALK3
QD expression affected the motility of the cells,
standard in vitro wound-healing assays were performed.
There was no difference in motility rates among Dox-
treated and untreated 429T, 429T-A44 and 429T-A54
cells (data not shown). When cells were observed during
the progress of cell migration (i.e.a t2 4h o u r sa f t e r
wounding), Dox-treated 429T-A44 and 429T-A54 cells
possessed a more spindle-shaped morphology as they
migrated into the manufactured wound space with cells
possessing long, cytoplasmic projections extending in
the direction of cell movement ( F i g .5 B ) .I n t e r e s t i n g l y ,
429T and 429T-ALK3
QD cells are poorly invasive
through matrices composed of either rat tail collagen or
gelatin, regardless of Dox-treatment (data not shown).
This lack of invasiveness is identical to the parental
OVCA429 cell line (Mujoomdar & Nachtigal, unpub-
lished observations). Taken together, these data provide
further validation that ALK3
QD expression in OVCA429
cells results in morphological changes paralleling the
observed alterations in EMT marker expression.
A critical step controlling ovarian cancer metastasis is
the ability of EOC cells to adhere to surfaces at second-
ary sites [1]. The ALK3
QD-mediated decreases in b1-
and b3-integrin mRNA expression in 429T-ALK3
QD
ovarian cancer cells would predict a decrease in cell
adhesion. Timed cell-detachment assays demonstrated
that Dox-treated 429T-ALK3
QD cells have increased
sensitivity to trypsinization when compared to control
cells (Fig. 6A). To directly investigate the adhesive prop-
erties of these cells to specific substrates, we performed
adhesion assays using tissue culture dishes precoated
with the extracellular matrix (ECM) components fibro-
nectin (FN) and vitronectin (VTN), which are produced
Figure 4 ALK3
QD signalling induces EMT marker expression and reduces b1-and b3-integrin expression. Quantitative RT-PCR was
performed on total RNA isolated from 429T-ALK3
QD cells, and 429T control cells, treated with Dox for 2 d, or left untreated. Human gene-
specific primers were used to detect mRNA expression of the EMT markers Snail (SNAI1), Slug (SNAI2), and E-cadherin (CDH1). Quantification of
expression of beta- integrins [b1 (ITGB1), and b3 (ITGB3)], and the extracellular matrix components, fibronectin (FN1) and vitronectin (VTN) was
also performed. Induction of ID1 and ID3 mRNA expression by ALK3
QD served as a positive control. GAPDH mRNA expression was used for
normalization, and the fold change in mRNA expression was calculated by the ratio of Dox-treated versus untreated cell samples.
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429T-ALK3
QD cell lines had a reduced ability to attach
to FN- and VTN-coated wells when induced to express
ALK3
QD (Fig. 6B&C).
Multicellular aggregates of EOC cells, termed spher-
oids, are present in the ascites of patients and are
hypothesized to play an essential role in ovarian cancer
metastasis [33]. Cell-cell cohesion in spheroids is
mediated primarily by cadherins junctions and integrin
interactions [34]. Thus, we sought to determine whether
the reduced E-cadherin and b1-/b3-integrin expression
due to ALK3
QD signalling affects the ability of
OVCA429 cells to form spheroids. After culturing cells
for 2 d on Ultra-Low Attachment cluster plates, Dox-
treated 429T-ALK3
QD spheroids were smaller in size
and less dense-appearing than untreated cells and 429T
control cells (Figure 7).
Discussion
Primary cultures of normal human OSE cells and EOC
cells possess an intact BMP4 signalling pathway, yet
there are important differences between the response of
normal OSE cells to exogenous BMP4 and that of EOC
cells [2,23]. For example, primary human EOC cells
Figure 5 ALK3
QD signalling induces an EMT-like morphology of OVCA429 cells. (A) Subconfluent monolayer cultures of 429T-A44 and
429T-A54 cells, and 429T control cells, were treated with Dox for 2 d, or left untreated (inset). At confluence, both 429T-A44 and 429T-A54 cells
exhibited a greater proportion of refractile, spindle-shaped cells versus 429T control cells. (B) All cells were grown and treated as described
above, but after 2 d a scratch wound was generated. Long cytoplasmic projections extend into the wound space in Dox-treated 429T-A44 and
429T-A54 cells as compared with 429T control cells. Photo images were captured at 100 × original magnification.
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proto-oncogene expression than do normal human OSE
cells (~10-15 fold in EOC cells, compared to 2-3 fold in
normal OSE)[2]. The differential response to BMP4 sig-
nalling between OSE and EOC cells is unlikely to be
due to altered BMP4 receptor expression levels since we
observed no significant differences in the mRNA level of
ALK3 or BMPR2, and expression of ALK6 mRNA was
largely undetectable in all primary cell samples. Addi-
tionally, BMPR2, Smad1 and Smad5 protein levels were
similar in primary OSE and EOC cell samples (Shepherd
& Nachtigal, unpublished observations).
To observe the effect of autonomous BMP signalling
in EOC cells, we chose to express the constitutively-
active mutant BMP type I receptor ALK3
QD in
OVCA429 ovarian cancer cells. Several studies have
used mutant BMP receptor expression to obtain insight
into the role of BMP signalling in human cancer cells.
For example, dominant-negative BMPR2 affects the
growth of human breast cancer cells in vitro by blocking
cells in G1 of the cell cycle[35]. Constitutively-active
ALK6
QD receptor expression decreases the proliferation
of human prostate cancer cells as well as their ability to
form tumours in nude mice[36], whereas blocking BMP
signalling by expression of dominant-negative BMPR2
enhances prostate cancer tumorigenicity[37]. No mutant
BMP receptors have been identified in primary human
EOC cells, however an intact autocrine BMP4 pathway
exists to induce EOC cell spreading, and increased adhe-
sion, motility and invasion[2,23]. Moreover, cell migra-
tion is greatly reduced by blocking this autocrine BMP4
signalling pathway with the BMP2/4 antagonist Noggin
[23]. Established human EOC cell lines are responsive to
exogenous BMP4 ligand at the level of target gene
expression, yet appear particularly unaffected in terms
of other phenotypic changes observed in primary EOC
cell samples from patients[2,23]. By utilizing the induci-
ble expression of a constitutively-active ALK3
QD recep-
tor in OVCA429 ovarian cancer cells, we provide
additional evidence for the contribution of BMP signal-
ling to affect cellular morphology and adherence in
EOC cells, and now extend these findings with direct
analysis of its impact on EOC metastasis in vivo.
In this report we demonstrate that constitutive BMP
signalling through the mutant ALK3 receptor induces
EMT markers, consistent with our findings observed in
primary EOC cells[23]. EMT is commonly associated
with aggressive cancer cell behaviour[38]. Indeed, ecto-
pic overexpression of Snail and Slug in the SkOV3
human ovarian cancer cell line enhances their motility,
invasiveness and tumorigenicity[39]. The precise role for
EMT in ovarian cancer pathogenesis, however, is not
straightforward [40]. Although decreased E-cadherin
expression is a hallmark of EMT and is usually
Figure 6 ALK3
QD signalling decreases OVCA429 cell adhesion.
(A) ALK3
QD expression increases trypsin-sensitivity of OVCA429 cells.
Subconfluent monolayer cultures of 429T-ALK3
QD cells (clones A44
and A54), and 429T control cells, were treated with Dox for 2 d
(+Dox), or left untreated (-Dox). At confluence, cells were gently
trypsinized for 2 min, and the number of suspended cells was
scored. The final proportion of released cells was significantly
higher in Dox-treated 429T-A44 and -A54 cells versus 429T control
cells. (B,C) ALK3
QD expression decreases the adhesion of OVCA429
cells to the ECM components fibronectin (FN) and vitronectin (VTN).
Cells were cultured in the presence or absence of Dox,
radiolabelled with
3H-amino acids, trypsinized, counted, and
allowed to recover in serum-containing media. Cells were then
seeded at 1 × 10
5 cells per well that were pre-coated with FN and
VTN and number of attached cells were quantified. Dox-treated
429T-A44 and -A54 cells had a significantly-reduced ability to attach
to both FN and VTN as compared with untreated cells, and the
429T control cells. (*, p < 0.05; **, p < 0.01; ***, p < 0.001)
Shepherd et al. Journal of Ovarian Research 2010, 3:5
http://www.ovarianresearch.com/content/3/1/5
Page 10 of 14correlated with a higher degree of malignancy in most
other carcinomas, forced overexpression of E-cadherin
in immortalized human OSE cells enhances pre-neoplas-
tic features in vitro and establishes tumour-forming abil-
ity in vivo [41,42]. Our data independently supports this
finding since ALK3
QD expression led to morphological
alterations and changes in gene expression consistent
with EMT in vitro, yet resulted in a decreased ability to
produce ascites and form tumours in vivo.P e r h a p st h e
functional role of EMT in ovarian cancer is an exception
to norm among epithelial-derived malignancies[40] and
represents a key process underlying the unique mode of
metastasis, i.e. direct dissemination into the peritoneal
cavity, observed in this type of carcinoma[1,33].
ALK3QD-expressing OVCA429 cells exhibited
decreased ability to form spheroids as well as reduced
cell-substratum adhesion with concomitant alterations
in the expression of a number of genes encoding integ-
rins and ECM components. Le Page and colleagues have
recently demonstrated that BMP2 treatment of several
ovarian cancer cell lines also reduces the cell-cell cohe-
sion during spheroid formation [43]; however, evidence
for the molecular mechanism was not presented. BMP
signalling has been shown to alter the expression of
integrins and their substrates present in the ECM in
several cell types, including EOC cells. For example,
a5b1 and avb3 expression is increased in osteoblasts in
response to BMP signalling resulting in increased
mesenchymal cell adherence[44-46]. Altered expression
of b-integrins has numerous implications in human can-
cer pathogenesis. Conditional loss of b1-integrin reduces
mammary tumour formation in transgenic mice[47].
Specific to ovarian cancer, it has been postulated that
b1-integrin expression by EOC cells functions during
metastasis to promote cell adhesion to the peritoneal
mesothelial surfaces during tumour implantation[48-50].
In addition, blocking b1-integrin with interfering antibo-
dies disaggregates EOC spheroids and reduces cell adhe-
sion, spheroid formation, and attachment to peritoneal
surfaces [48,51]. Coordinated expression of b3-integrin
is also involved in EOC cell adhesion, and b3-integrin
interaction with vitronectin via av-integrin promotes
EOC cell proliferation, motility, and ECM degradation
[52,53]. In contrast, Kaur and colleagues recently
demonstrated that forced avb3-integrin overexpression
in SkOV3ip1 cells increases cell adhesion in vitro yet
reduces both invasion and their ability to form second-
ary tumours in mice; clinical data from this same report
implicates that av/b3-integrin expression may represent
a favourable prognostic marker in ovarian cancer [54].
Ascites-derived primary human EOC cells treated with
BMP4 leads to increased b1-a n db3-integrin mRNA
expression and correlates with increased adherence to a
variety of ECM substrates in vitro [23]. In this report,
Figure 7 ALK3
QD signalling reduces OVCA429 spheroid formation. 429T-ALK3
QD cells and 429T control cells were grown on Ultra-Low
Attachment cluster plates for 2 d while treated with Dox or left untreated. ALK3
QD-expressing cells produced smaller multicellular aggregates, or
spheroids, than untreated 429T-ALK3
QD cells and 429T controls. Scale bar = 200 μm.
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integrins caused by an aberrant constitutively-active
BMP signalling pathway in a more malignant variant of
EOC cells (i.e. the OVCA429 cell line) decreases cell
adhesion in vitro and thereby leads to reduced ascites
and intraperitoneal tumour formation in vivo.W h e t h e r
BMP signalling regulates b1-a n db3-integrin expression
directly or indirectly to affect EOC cell adhesion during
specific steps of ovarian tumorigenesis requires further
investigation. The recent work by Kaur et al specifically
examined ectopic overexpression of b3-integrin in SkO-
V3ip1 cells[54], whereas other studies have evaluated
endogenous integrin expression and function within sev-
eral other EOC cell lines (CaOV3, SkOV3, OVCAR3,
OVCAR5, SW626, OV-MZ-6, 36M2)[48-53]. The major-
ity of these studies suggest that intact integrin function
inherent to EOC cells is necessary for adhesion to ECM
and peritoneal surfaces in the promotion of EOC metas-
tasis. From our standpoint, it is imperative to perform
future studies using both ascites-derived primary EOC
cells and established EOC cell lines to help clarify the
mechanisms underlying the observed differences in
integrin-mediated cell adhesion on the malignant beha-
viour among these cell types.
Differential effects of BMP signalling in vitro com-
pared to in vivo have been observed in other tumour
models. For example, Langenfeld and colleagues demon-
strate that BMP2 induces human lung adenocarcinoma
A549 cell proliferation in vitro in the presence of serum;
but when injected into nude mice BMP2-expressing
A549 cells have reduced subcutaneous tumour growth,
while development of lung metastases is augmented[55].
They suggest that the cellular response to BMP signal-
ling is dependent upon additional factors in specific
tumour microenvironments. Our model has ALK3 sig-
nalling constitutively maintained in a cell-autonomous
fashion thereby impacting OVCA429 cells directly.
From this, we propose that the decreased EOC cell
adhesion observed in vitro is a critical factor contribut-
ing to reduced intraperitoneal ascites and tumour for-
mation in vivo as compared with control cells. It will be
imperative to further investigate the functional impact
of BMP ligands and antagonists on EOC cells versus the
surrounding tissue microenvironment during ovarian
tumour formation and metastasis.
Conclusions
In summary, we propose that dysregulated BMP signal-
ling is implicated in EOC cell exfoliation from the pri-
mary tumour site and subsequent dissemination during
ovarian cancer progression. Overactive BMP signalling
mediates efficient ovarian cancer cell detachment from
the primary tumour; however, at later steps of ovarian
cancer progression, down-regulation of BMP signalling
may be necessary to establish tumour cell adherence
and secondary metastasis formation. To this end, we are
currently developing additional in vivo models of ovar-
ian cancer to address the implication of modulated BMP
signalling on each step from initiation to metastasis.
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